Search

Difenoxin

It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide … It is approved by the FDA to treat acute and chronic diarrhea.

rhMBL

MBL forms different oligomers but must form at least a tetramer to be active. … rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL).

Bimatoprost

Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. … [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug

Sodium zirconium cyclosilicate

[L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and … Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that

NKG2D-ACE2 CAR-NK Cell

These cells are prepared as universal off-the-shelf CAR-NK cells from cord blood with NKG2D-ACE2 proteins engineered as part of the CARs; the cell secretes IL-15 and GM-CSF. … Chimeric antigen receptors (CARs) are artificial receptors consisting of an antibody-derived antigen binding domain and transmembrane and signaling domains from T-cell receptor signalling moieties.

Equine Botulinum Neurotoxin F Immune FAB2

Equine Botulinum Neurotoxin F Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype F.

Duvelisib

[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]

Zosuquidar

Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with t...

Aluminium phosphate

Sulfapyridine

No longer prescribed.